KR20220154801A - 질환의 치료를 위한 파르네소이드 x 수용체 작용제 - Google Patents

질환의 치료를 위한 파르네소이드 x 수용체 작용제 Download PDF

Info

Publication number
KR20220154801A
KR20220154801A KR1020227036071A KR20227036071A KR20220154801A KR 20220154801 A KR20220154801 A KR 20220154801A KR 1020227036071 A KR1020227036071 A KR 1020227036071A KR 20227036071 A KR20227036071 A KR 20227036071A KR 20220154801 A KR20220154801 A KR 20220154801A
Authority
KR
South Korea
Prior art keywords
compound
disease
pharmaceutically acceptable
acceptable salt
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227036071A
Other languages
English (en)
Korean (ko)
Inventor
케네스 송
휴버트 첸
브랜디 와그너
니콜라스 디 스미스
Original Assignee
메타크린, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메타크린, 인크. filed Critical 메타크린, 인크.
Publication of KR20220154801A publication Critical patent/KR20220154801A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227036071A 2020-03-18 2021-03-17 질환의 치료를 위한 파르네소이드 x 수용체 작용제 Pending KR20220154801A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062991292P 2020-03-18 2020-03-18
US62/991,292 2020-03-18
US202063069667P 2020-08-24 2020-08-24
US63/069,667 2020-08-24
US202163140735P 2021-01-22 2021-01-22
US63/140,735 2021-01-22
PCT/US2021/022786 WO2021188688A1 (en) 2020-03-18 2021-03-17 Farnesoid x receptor agonists for the treatment of disease

Publications (1)

Publication Number Publication Date
KR20220154801A true KR20220154801A (ko) 2022-11-22

Family

ID=77771857

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227036071A Pending KR20220154801A (ko) 2020-03-18 2021-03-17 질환의 치료를 위한 파르네소이드 x 수용체 작용제

Country Status (12)

Country Link
US (1) US20230131804A1 (enExample)
EP (1) EP4121048A4 (enExample)
JP (1) JP7851856B2 (enExample)
KR (1) KR20220154801A (enExample)
CN (4) CN120732855A (enExample)
AU (1) AU2021240001A1 (enExample)
BR (1) BR112022018651A2 (enExample)
CA (1) CA3172205A1 (enExample)
IL (1) IL296539A (enExample)
MX (1) MX2022011579A (enExample)
TW (1) TWI895384B (enExample)
WO (1) WO2021188688A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3852748B1 (en) 2018-09-18 2025-09-03 Eli Lilly and Company Farnesoid x receptor agonists and uses thereof
CN120227340A (zh) 2020-03-18 2025-07-01 伊莱利利公司 法尼醇x受体激动剂的制剂
JP7664278B2 (ja) * 2020-03-18 2025-04-17 オルガノボ，インク． ファルネソイドｘ受容体アゴニストの結晶質形態
CN117018000B (zh) * 2023-08-29 2025-01-28 东莞市东南部中心医院(东莞市东南部中医医疗服务中心) 4-胆甾烯-3-酮在制备预防或治疗炎症性肠病药物中的应用
WO2026149323A1 (en) * 2025-01-07 2026-07-16 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods of using mitochondrial uncouplers and glp-1 receptor agonists
CN120837611B (zh) * 2025-09-22 2025-12-16 吉林大学 一种经鼻给药的司美格鲁肽制剂及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) * 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
AU2016233579A1 (en) * 2015-03-13 2017-10-12 Salk Institute For Biological Studies Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors
WO2017049176A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3350165B1 (en) 2015-09-16 2023-07-26 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
EP3350166A4 (en) * 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
AU2018236275B2 (en) * 2017-03-15 2022-05-12 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
DK3596053T3 (da) * 2017-03-15 2023-09-25 Organovo Inc Farnesoid-x-receptoragonister og anvendelser deraf
EP3852748B1 (en) * 2018-09-18 2025-09-03 Eli Lilly and Company Farnesoid x receptor agonists and uses thereof

Also Published As

Publication number Publication date
IL296539A (en) 2022-11-01
CN120732854A (zh) 2025-10-03
EP4121048A4 (en) 2024-06-12
US20230131804A1 (en) 2023-04-27
EP4121048A1 (en) 2023-01-25
JP7851856B2 (ja) 2026-04-27
CA3172205A1 (en) 2021-09-23
JP2023518397A (ja) 2023-05-01
BR112022018651A2 (pt) 2022-11-29
AU2021240001A1 (en) 2022-10-13
CN115666559A (zh) 2023-01-31
WO2021188688A1 (en) 2021-09-23
TWI895384B (zh) 2025-09-01
CN120732855A (zh) 2025-10-03
CN120732856A (zh) 2025-10-03
TW202143961A (zh) 2021-12-01
MX2022011579A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
US20220323414A1 (en) Farnesoid x receptor agonists for the treatment of disease
TWI895384B (zh) 用於治療疾病之法尼醇x受體促效劑
AU2026200681A1 (en) Treatment for fibrosis
US11197870B2 (en) Treatment for hepatic fibrosis
AU2016323468A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
JP2017528431A (ja) 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム
KR20170049606A (ko) 간 질환을 치료하기 위한 오메가-3 지방산과 sglt-2 억제제의 조합
KR20210092754A (ko) Nafld 및 nash의 병용 치료
KR20190117632A (ko) Ppar 효현제와 fxr 효현제의 병용
TW202114672A (zh) 使用fxr促效劑的肝臟疾病之組合治療
JP2020536866A (ja) Ａｃｃ阻害剤を含む併用療法
US20190175619A1 (en) Treatment of fibrosis, and inhibition of fibrosis in non-alcoholic fatty liver disease patients
TW202143958A (zh) 用於治療疾病之法尼醇x(farnesoid x)受體促效劑
HK40131843A (en) Farnesoid x receptor agonists for the treatment of diseases
HK40131844A (en) Farnesoid x receptor agonists for the treatment of disease
CN114401745A (zh) 包含fxr激动剂的治疗
Maroni¹ et al. The pathophysiology of gut-liver
US20220362263A1 (en) Treatment for fibrosis and inhibition of fibrosis
Magdaleno et al. Animal Models When Examining the Gut-Liver Axis
JP2019537607A (ja) 非アルコール性脂肪性肝疾患の患者における線維化の抑制
HK1237676A1 (en) Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
Sumida et al. An eBook on Diabetes

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902